Enfortumab vedotin promotes PD-L1 expression in urothelial carcinoma via NF-κB and STAT3 pathways highlighting mechanisms of immune evasion and potential for combination therapyHirohito Naito, Mikio Sugimoto|BMC Immunology|2025Cited by 2